The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hep C Drug Boceprevir is Faster and Better

Back to News Homepage

Next

May 23 Could Bring Approval for Vertex's Hep C Drug

FDA Backs Telaprevir for Having High Hepatitis C Cure Rate

May 4, 2011

Print this page

Just a day after doling out similar praise for a comparable drug from Merck, an FDA panel backed the approval of Vertex’s telaprevir, largely due to their computation that this drug’s Hepatitis C cure rate goes far beyond the current therapy’s ability.

Vertex’s hepatitis C drug aces review

Telaprevir cures more people more quickly than current options

April 27, 2011 | By Robert Weisman, Globe Staff

A drug developed by Vertex Pharmaceuticals Inc. cures more patients with the hepatitis C virus in less time than existing therapies, according to a briefing document filed yesterday by Food and Drug Administration staffers who reviewed the company’s application for approval.

Continue reading this entire article:
http://archive.boston.com/business/healthcare/articles/2011/04/27/hepatitis_c_drug_from_vertex_aces_review/

No Comments - be the first!
Share
Share

Previous

Hep C Drug Boceprevir is Faster and Better

Back to News Homepage

Next

May 23 Could Bring Approval for Vertex's Hep C Drug

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.